RGD
RGD is a peptide that delivers attached compounds to targets such as thrombus or tumor cells; it enhances efficacy of anticancer and anti-aggregation or anti-adhesion compounds. RDG binds integrins on the surfaces of cells.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18958286
| Cas No. |
99896-85-2 |
|---|---|
| Purity |
≥95% |
| Formula |
C12H22N6O6 |
| Formula Wt. |
346.3 |
| Chemical Name |
Arginyl-glycyl-aspartic acid |
| IUPAC Name |
(2S)-2-[[2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid |
| Appearance |
White to off white powder |
Guo Z, He B, Jin H, et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering. Biomaterials. 2014 Apr 30. [Epub ahead of print]. PMID: 24794924.
Li Y, Zheng X, Sun Y, et al. RGD-fatty alcohol-modified docetaxel liposomes improve tumor selectivity in vivo. Int J Pharm. 2014 Apr 4;468(1-2):133-141. [Epub ahead of print]. PMID: 24709214.
Zhao M, Wang C, Jiang X, et al. Synthesis of RGD containing peptides and their bioactivities. Prep Biochem Biotechnol. 2002 Nov;32(4):363-80. PMID: 12455829.
Preferred conformations of RGDX tetrapeptides to inhibit the binding of fibrinogen to platelets.
Park HS, Kim C, Kang YK. Biopolymers. 2002 Apr 15;63(5):298-313. PMID: 11877740.
